gene in patients relapsing following cure Using the BCL2 antagonist venetoclax. 66 Resistance to those agents is connected to these mutations in all around 70% of cases, While they tend to be subclonal as well as their precise job triggering resistance should be demonstrated. Genetic susceptibili